The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
Príomhchruthaitheoirí: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
BMC
2025-01-01
|
Sraith: | BMC Complementary Medicine and Therapies |
Ábhair: | |
Rochtain ar líne: | https://doi.org/10.1186/s12906-025-04753-w |
Míreanna comhchosúla
Míreanna comhchosúla
-
Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
de réir: Ana Pilar Pérez-Acevedo, et al.
Foilsithe / Cruthaithe: (2020-12-01) -
Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
de réir: Elmar Graessel, et al.
Foilsithe / Cruthaithe: (2024-10-01) -
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
de réir: Anna Gościniak, et al.
Foilsithe / Cruthaithe: (2024-11-01) -
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
de réir: Zackary Montoya, et al.
Foilsithe / Cruthaithe: (2020-09-01) -
El cannabidiol y sus indicaciones en psiquiatría
de réir: Juan Fernando Muñoz Ramírez
Foilsithe / Cruthaithe: (2021-03-01)